Literature DB >> 29343569

Myxoma Virus M083 Is a Virulence Factor Which Mediates Systemic Dissemination.

A M Wolfe1, K M Dunlap2, A C Smith1, M Y Bartee2, E Bartee3.   

Abstract

Poxviruses are large, DNA viruses whose protein capsid is surrounded by one or more lipid envelopes. Embedded into these lipid envelopes are three conserved viral proteins which are thought to mediate binding of virions to target cells. While the function of these proteins has been studied in vitro, their specific roles during the pathogenesis of poxviral disease remain largely unclear. Here we present data demonstrating that the putative chondroitin binding protein M083 from the leporipoxvirus myxoma virus is a significant virulence factor during infection of susceptible Oryctolagus rabbits. Removal of M083 results in a reduced capacity of virus to spread beyond the regional lymph nodes and completely eliminates infection-mediated mortality. In vitro, removal of M083 results in only minor intracellular replication defects but causes a significant reduction in the ability of myxoma virus to spread from infected epithelial cells onto primary lymphocytes. We hypothesize that the physiological role of M083 is therefore to mediate the spread of myxoma virus onto rabbit lymphocytes, allowing these cells to disseminate virus throughout infected rabbits.IMPORTANCE Poxviruses represent both a class of human pathogens and potential therapeutic agents for the treatment of human malignancy. Understanding the basic biology of these agents is therefore significant to human health in a variety of ways. While the mechanisms mediating poxviral binding have been well studied in vitro, how these mechanisms impact poxviral pathogenesis in vivo remains unclear. The current study advances our understanding of how poxviral binding impacts viral pathogenesis by demonstrating that the putative chondroitin binding protein M083 plays a critical role during the pathogenesis of myxoma virus in susceptible Oryctolagus rabbits by impacting viral dissemination through changes in the transfer of virions onto primary splenocytes.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  binding proteins; myxoma virus; pathogenesis; virulence factor

Mesh:

Substances:

Year:  2018        PMID: 29343569      PMCID: PMC5972901          DOI: 10.1128/JVI.02186-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  The complete DNA sequence of myxoma virus.

Authors:  C Cameron; S Hota-Mitchell; L Chen; J Barrett; J X Cao; C Macaulay; D Willer; D Evans; G McFadden
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

2.  Myxoma virus: propagation, purification, quantification, and storage.

Authors:  Sherin E Smallwood; Masmudur M Rahman; Dorothy W Smith; Grant McFadden
Journal:  Curr Protoc Microbiol       Date:  2010-05

3.  Recombinant myxoma virus lacking all poxvirus ankyrin-repeat proteins stimulates multiple cellular anti-viral pathways and exhibits a severe decrease in virulence.

Authors:  Stephanie A Lamb; Masmudur M Rahman; Grant McFadden
Journal:  Virology       Date:  2014-07-26       Impact factor: 3.616

4.  Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.

Authors:  J W Hooper; D M Custer; E Thompson
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

5.  Characterization of the major capsid proteins of myxoma virus particles using MALDI-TOF mass spectrometry.

Authors:  Alicja Zachertowska; Dyanne Brewer; David H Evans
Journal:  J Virol Methods       Date:  2005-10-13       Impact factor: 2.014

6.  Role of the serine-threonine kinase PAK-1 in myxoma virus replication.

Authors:  J B Johnston; John W Barrett; Wen Chang; Che-Sheng Chung; Wei Zeng; Jennefer Masters; Melissa Mann; Fuan Wang; Jingxin Cao; Grant McFadden
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  A virulence factor of myxoma virus colocalizes with NF-kappaB in the nucleus and interferes with inflammation.

Authors:  Christelle Camus-Bouclainville; Laurence Fiette; Sophie Bouchiha; Béatrice Pignolet; Dorian Counor; Cédric Filipe; Jacqueline Gelfi; Frédérique Messud-Petit
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 8.  Oncolytic myxoma virus: the path to clinic.

Authors:  Winnie M Chan; Masmudur M Rahman; Grant McFadden
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

9.  Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans.

Authors:  Chwan Hong Foo; Huan Lou; J Charles Whitbeck; Manuel Ponce-de-León; Doina Atanasiu; Roselyn J Eisenberg; Gary H Cohen
Journal:  Virology       Date:  2009-01-21       Impact factor: 3.616

10.  Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen.

Authors:  Pavlo Sakhatskyy; Shixia Wang; Te-Hui W Chou; Shan Lu
Journal:  Virology       Date:  2006-08-21       Impact factor: 3.616

View more
  3 in total

1.  Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme.

Authors:  Chase Burton; Arabinda Das; Daniel McDonald; William A Vandergrift; Sunil J Patel; David Cachia; Eric Bartee
Journal:  Oncolytic Virother       Date:  2018-11-19

2.  Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxviruses.

Authors:  Erica B Flores; Mee Y Bartee; Eric Bartee
Journal:  PLoS One       Date:  2020-04-30       Impact factor: 3.240

3.  Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus.

Authors:  Chase Burton; Mee Y Bartee; Eric Bartee
Journal:  Oncolytic Virother       Date:  2019-12-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.